(+)-Neoalbaconol
(+)-Neoalbaconol is a selective Akt/PDK1 inhibitor (with an IC50 of 10 μM against hPDK1). (+)-Neoalbaconol selectively inhibits cancer cell proliferation, and induces energy depletion, apoptosis, autophagy and necroptosis in cancer cells. In addition, (+)-Neoalbaconol downregulates cIAP1/2 and TRAFs to activate non-canonical NF-κB and promote TNFα transcription, blocks EGFR-mediated VEGF production and receptor activation, and mediates cell necrosis via the RIPK3-ROS-dependent pathway. (+)-Neoalbaconol can be used in research related to nasopharyngeal carcinoma, melanoma, breast cancer and gastric cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 2779545-15-0
- Formel: C22H34O3
- Molecular Weight:346.50
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | EC50 |
11.09 μM
Compound: 37
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 34653771] |
| MCF7 | EC50 |
11.32 μM
Compound: 37
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 34653771] |
In Vitro
(+)-Neoalbaconol (20-100 μM) dose-dependently inhibits PDK1 kinase activity, with near-complete inhibition at 100 μM[1].
(+)-Neoalbaconol (50 μM; 7.5-18 μM IC50 range) selectively inhibits proliferation of diverse cancer cell lines, with highest potency against C666-1 (IC50 ~10 μM), HK1 (IC50 ~18 μM), and ZR-75-1 (IC50 ~7.5 μM) cells, and no effect on normal immortalized cell lines at 50 μM[1].
(+)-Neoalbaconol (40 μM) induces necroptosis in C666-1 and HK1 cells, characterized by necrotic morphology, increased RIP1/RIP3 interaction, and viability rescue by necrostatin-1[1].
(+)-Neoalbaconol (0.625-40 μM; 8 h-5 days) targets PDK1 to inhibit the PI3-K/Akt pathway and its downstream metabolic regulator HK2 in C666-1 and HK1 cells, suppressing Akt phosphorylation and downstream signaling, and reducing HK2 expression[1].
(+)-Neoalbaconol (40 μM; 4-24 h) inhibits glucose consumption and ATP generation in C666-1 cells, with ATP depletion driving cell death that is partially rescued by Akt overexpression[1].
(+)-Neoalbaconol (6.25-50 μM; 72 h) dose-dependently inhibits the viability of MDA-MB-231, MCF-7, and MX-1 human breast cancer cells in vitro (reducing viability by up to 82.06% at 50 μM) without affecting non-cancerous MCF-10A breast epithelial cells[3].
(+)-Neoalbaconol (2.5-20 μM; 2 week) dose-dependently inhibits anchorage-independent colony formation of MDA-MB-231 human breast cancer cells in vitro, reducing colony counts by up to ~80% at 20 μM over 2 weeks[3].
(+)-Neoalbaconol (2.5-10 μM; 24 h) inhibits VEGF-induced proliferation of HUVECs in vitro, reducing viability by 21.02% at 10 μM after 24 h[3].
(+)-Neoalbaconol (2.5-5 μM; 6 h) dose-dependently inhibits VEGF-induced migration of HUVECs in vitro, reducing migrated cell counts by 56.35% at 2.5 μM and 83.26% at 5 μM after 6 h[3].
(+)-Neoalbaconol (2.5-5 μM; 30 min pretreatment, followed by 4-6 h incubation) dose-dependently inhibits VEGF-induced invasion of HUVECs in vitro, reducing invasive cell counts by 60.33% at 2.5 μM and 80.26% at 5 μM after 4-6 h[3].
(+)-Neoalbaconol (2.5-5 μM; 6-8 h) dose-dependently inhibits VEGF-induced capillary tube formation of HUVECs in vitro, reducing tube counts by 82.21% at 2.5 μM and 92.04% at 5 μM after 6-8 h[3].
(+)-Neoalbaconol (2.5-20 μM; 4-12 h) dose- and time-dependently reduces VEGF secretion by MDA-MB-231 human breast cancer cells in vitro, decreasing VEGF levels by up to ~55% at 20 μM after 12 h[3].
(+)-Neoalbaconol (5-10 μM; 30 min pretreatment, followed by VEGF stimulation) dose-dependently inhibits VEGF-induced activation of the VEGFR/EGFR/Src/STAT3 signaling pathway in HUVECs in vitro, reducing p-VEGFR, p-EGFR, p-Src, and p-STAT3 levels at 5 and 10 μM[3].
(+)-Neoalbaconol (5-20 μM; 24-48 h) induces dose- and time-dependent cell death in C666-1 cells, reaching ~32% cell death at 20 μM over 48 h[1].
(+)-Neoalbaconol (40 μM; 24 h) induces apoptosis in C666-1 cells, with 78.2% of cells staining positive for annexin V, and activation of caspase and PARP-1 cleavage[1].
(+)-Neoalbaconol (20-40 μM; 6-8 h) induces active autophagy in C666-1, HK1, and CNE1 cells, as shown by LC3-II upregulation, p62 degradation, YFP-LC3 puncta formation, and confirmed autophagic flux[1].
(+)-Neoalbaconol (20-40 μM; 0-24 h) induces RIPK1- and RIPK3-dependent necroptotic cell death in C666-1 and HK1 human nasopharyngeal carcinoma cells, as evidenced by MLKL phosphorylation, progressive membrane integrity loss, and reduced cell death with RIPK knockdown[2].
(+)-Neoalbaconol (20-40 μM; 1, 8 h) triggers auto-ubiquitination and subsequent proteasomal degradation of cIAP1 and cIAP2, and reduces protein levels of TRAF2 and TRAF6, in C666-1 and HK1 human nasopharyngeal carcinoma cells[2].
(+)-Neoalbaconol (0-40 μM; 8, 24 h) reduces K63-linked ubiquitination of RIPK1, inhibits the canonical NF-κB pathway, and activates the non-canonical NF-κB pathway in C666-1 human nasopharyngeal carcinoma cells[2].
(+)-Neoalbaconol (40 μM; 24 h) induces independent apoptotic, necroptotic, and autophagic pathways in C666-1 and HK1 cells, with autophagy acting as a survival mechanism, and apoptosis/necroptosis driving cell death[1].
(+)-Neoalbaconol (40 μM; 0-12 h, 48 h) induces autocrine TNFα production in NA-sensitive cancer cell lines (C666-1, HK1, MX-1, AGS-EBV) in a RIPK1-dependent manner, and autocrine TNFα contributes to NA-induced necroptotic cell death[2].
(+)-Neoalbaconol (40 μM; 1, 48 h) relies on the non-canonical NF-κB pathway (mediated by IKKα) for induced TNFα production and necroptotic cell death in C666-1 human nasopharyngeal carcinoma cells, while the canonical NF-κB pathway is not involved[2].
(+)-Neoalbaconol (40 μM; 12, 24 h) induces RIPK3-dependent ROS production originating from mitochondrial complex I, which contributes to necroptotic cell death in C666-1 human nasopharyngeal carcinoma cells[2].
(+)-Neoalbaconol (20 μM) induces apoptosis in MDA-MB-231 and MX-1 human breast cancer cells in vitro, reducing viable cell counts by 21.55% and 30.08% respectively at 20 μM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:C666-1 nasopharyngeal carcinoma cells
-
Concentration:5, 10, 20 μM
-
Incubation Time:24 h; 48 h
-
Result:Induced dose- and time-dependent cell death in C666-1 cells.
Reached cell death rates of ~7% at 5 μM, ~9% at 10 μM, and ~24% at 20 μM after 24 h.
Reached cell death rates of ~15% at 5 μM, ~19% at 10 μM, and ~32% at 20 μM after 48 h, with a statistically significant increase at 20 μM compared to control.
-
Cell Line:C666-1 nasopharyngeal carcinoma cells
-
Concentration:40 μM (annexin V-FITC/PI staining)
-
Incubation Time:24 h (annexin V-FITC/PI staining)
-
Result:Increased the percentage of annexin V-positive C666-1 cells to 78.2% after 24 h of 40 μM treatment.
Induced cleavage of caspases and PARP-1, confirming activation of the apoptotic pathway.
-
Cell Line:C666-1, HK1, CNE1 nasopharyngeal carcinoma cells
-
Concentration:20, 30, 40 μM (LC3/p62 immunoblotting); 40 μM (YFP-LC3 confocal microscopy, autophagic flux assay)
-
Incubation Time:8 h (LC3/p62 immunoblotting); 6 h (YFP-LC3 confocal microscopy)
-
Result:Upregulated endogenous LC3-II protein levels and reduced p62 protein levels in C666-1 cells.
Induced punctate aggregation of YFP-LC3 fluorescence in C666-1 cells, indicating autophagosome formation.
Increased autophagic vacuoles in treated cells as revealed by transmission electron microscopy.
Cotreatment with bafilomycin further elevated LC3-II levels and attenuated p62 reduction, confirming active autophagic flux.
-
Cell Line:C666-1, HK1 nasopharyngeal carcinoma cells
-
Concentration:20, 30, 40 μM (8 h short-term pathway inhibition); 0.625, 1.25, 2.5, 5, 10 μM (5 days long-term low-dose inhibition); 40 μM (8 h metabolic regulator mRNA/protein analysis)
-
Incubation Time:8 h (short-term pathway inhibition, metabolic regulator analysis); 5 days (long-term low-dose inhibition)
-
Result:Suppressed phosphorylation of Akt at Ser308 and Ser473 without altering PDK1 phosphorylation, and dose-dependently inhibited phosphorylation of downstream molecules TSC2, mTOR, and p70S6K1.
Inhibited Akt and mTOR phosphorylation with long-term low-dose treatment.
Suppressed TNFα-, EGF-, IL6-, and FBS-induced Akt activation after preincubation.
Specifically downregulated HK2 mRNA and protein levels in C666-1 and HK1 cells.
-
Cell Line:C666-1, HK1 nasopharyngeal carcinoma cells
-
Concentration:40 μM (+)-Neoalbaconol; 40 μM necrostatin-1; 20 μM zVAD-fmk; 5 μM 3-MA; 50 μM SP600125
-
Incubation Time:24 h; 1 h (SP600125 preincubation)
-
Result:Inhibition of autophagy with 3-MA enhanced (+)-Neoalbaconol-induced cell death.
Inhibition of apoptosis with zVAD-fmk or necroptosis with necrostatin-1 rescued cell viability.
Cotreatment with SP600125 (JNK inhibitor) further increased (+)-Neoalbaconol-induced cell death.
Activated JNK phosphorylation; inhibitors of apoptosis, necroptosis, autophagy, or JNK did not cross-inhibit other pathways.
-
Cell Line:human nasopharyngeal carcinoma C666-1, HK1, CNE1-LMP1 cells, human breast cancer MX-1 cells, human gastric cancer AGS-EBV cells, human amelanotic melanoma A375 cells
-
Concentration:40 μM (TNFα transcription, secretion analysis, viability assays with RIPK1 knockdown); 1, 2, 4 μg/mL neutralizing TNFα antibody (pre-treatment for viability assays)
-
Incubation Time:8 h (TNFα transcription analysis); 0, 4, 8, 12 h (TNFα secretion analysis); 1 h neutralizing TNFα antibody pre-treatment; 48 h siRNA transfection prior to NA treatment
-
Result:Induced a 3- to 15-fold increase of TNFα mRNA in NA-sensitive cell lines (C666-1, HK1, MX-1, AGS-EBV) after 8 h treatment, while NA-resistant cell lines (A375, CNE1-LMP1) showed less than a 2-fold induction.
Triggered TNFα secretion into culture medium over 12 h in NA-sensitive C666-1 and HK1 cells, while resistant CNE1-LMP1 cells showed low TNFα secretion.
Partially and dose-dependently rescued C666-1 and HK1 cells from induced death after pre-treatment with neutralizing TNFα antibody.
Blocked induced increases in TNFα mRNA and secretion after knockdown of RIPK1.
-
Cell Line:human nasopharyngeal carcinoma C666-1, HK1 cells
-
Concentration:20, 30, 40 μM (cIAP1/2, TRAF protein level analysis); 40 μM NA, 2 mM MG132 (proteasome inhibition assays); 40 μM NA (cIAP1/2 ubiquitination assays)
-
Incubation Time:8 h (cIAP1/2, TRAF protein level analysis; cIAP1/2 ubiquitination assays); 1 h (proteasome inhibition assays); 48 h plasmid transfection prior to NA treatment
-
Result:Reduced protein levels of cIAP1, cIAP2, XIAP, TRAF2, and TRAF6 in C666-1 and HK1 cells, but did not affect TRAF3, TRADD, or FADD levels.
Blocked NA-dependent decreases in cIAP1/2 protein levels after treatment with proteasome inhibitor MG132.
Enhanced auto-ubiquitination of cIAP1 and cIAP2.
-
Cell Line:human nasopharyngeal carcinoma C666-1 cells
-
Concentration:40 μM NA, 40 μM NAI, 5 μM BAY11-7082 (TNFα transcription, viability assays); 40 μM NA (TNFα transcription, secretion analysis with IKKα knockdown); varying doses (viability assays with IKKα knockdown)
-
Incubation Time:1 h inhibitor pre-treatment; 48 h siRNA transfection prior to NA treatment
-
Result:Did not affect NA-induced TNFα transcription or cell death after treatment with canonical NF-κB pathway inhibitors (NAI, BAY11-7082).
Reduced NA-induced TNFα mRNA levels and secretion, and rescued C666-1 cells from NA-induced death after knockdown of IKKα.
-
Cell Line:MDA-MB-231, MCF-7, MX-1, MCF-10A
-
Concentration:6.25, 12.5, 25, 50 μM
-
Incubation Time:72 h
-
Result:Reduced cell viability by 82.06% in MDA-MB-231 cells, 45.22% in MCF-7 cells, and 78.12% in MX-1 cells at 50 μM.
Showed no toxic effect on MCF-10A cells at 50 μM.
Decreased viability of MDA-MB-231, MCF-7, and MX-1 cells in a dose-dependent manner across 6.25, 12.5, 25, 50 μM.
Maintained MCF-10A viability near baseline across 6.25, 12.5, 25, 50 μM.
-
Cell Line:HUVECs
-
Concentration:2.5, 5, 10 μM
-
Incubation Time:24 h
-
Result:Reduced VEGF-induced HUVEC viability by 21.02% at 10 μM.
Inhibited VEGF-induced proliferation in a dose-dependent manner across 2.5, 5, 10 μM.
-
Cell Line:HUVECs
-
Concentration:2.5, 5 μM
-
Incubation Time:6 h
-
Result:Reduced VEGF-induced migrated cell counts by 56.35% at 2.5 μM compared to VEGF-only controls.
Reduced VEGF-induced migrated cell counts by 83.26% at 5 μM compared to VEGF-only controls.
Inhibited VEGF-induced HUVEC migration in a dose-dependent manner.
-
Cell Line:HUVECs
-
Concentration:2.5, 5 μM
-
Incubation Time:30 min pretreatment, followed by 4-6 h incubation
-
Result:Reduced VEGF-induced invasion by 60.33% at 2.5 μM compared to VEGF-only controls.
Reduced VEGF-induced invasion by 80.26% at 5 μM compared to VEGF-only controls.
Dramatically reduced VEGF-induced HUVEC invasiveness in a dose-dependent manner.
-
Cell Line:MDA-MB-231
-
Concentration:2.5, 5, 10, 20 μM (12 h incubation); 10 μM (4, 8, 12 h incubation)
-
Incubation Time:4-12 h
-
Result:Reduced VEGF levels by ~15% at 2.5 μM, ~35% at 5 μM, ~45% at 10 μM, and ~55% at 20 μM after 12 h incubation.
Reduced VEGF levels by ~30% at 4 h, ~40% at 8 h, and ~50% at 12 h at 10 μM.
Reduced VEGF secretion in dose- and time-dependent manners.
-
Cell Line:MDA-MB-231
-
Concentration:5, 10 μM
-
Incubation Time:30 min pretreatment, followed by EGF stimulation
-
Result:Inhibited EGF-induced phosphorylation of EGFR, Src, and STAT3 in a dose-dependent manner.
Achieved near-complete inhibition of p-EGFR at 10 μM.
Achieved partial inhibition of p-Src and p-STAT3 at 10 μM.
Left total protein levels of EGFR, Src, and STAT3 unchanged.
-
Cell Line:HUVECs
-
Concentration:5, 10 μM
-
Incubation Time:30 min pretreatment, followed by VEGF stimulation
-
Result:Inhibited VEGF-induced phosphorylation of VEGFR, EGFR, Src, and STAT3 in a dose-dependent manner.
Caused significant reduction in all phosphorylated proteins at 5 and 10 μM.
Left total protein levels of VEGFR, EGFR, Src, and STAT3 unchanged.
In Vivo
(+)-Neoalbaconol (40 mg/kg; i.p.; daily; 15 days) reduces average breast cancer xenograft volume by 53% and weight by 64%, while decreasing tumor microvessel density by 75.68% and proliferation index by 57.82% in athymic nude mice[3].
(+)-Neoalbaconol (2.5-5 μM; s.c.; single dose) reduces VEGF-induced microvessel formation by 69.20% and 84.62%, respectively, in C57BL/6 mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nu/nu nude mice (male, 4- to 6-week-old, subcutaneously injected with 5×106 C666-1 cells)[1]
-
Dosage:100 mg/kg
-
Administration:daily
-
Result:Reduced average tumor volume to 627 mm3 (vs. 1512 mm3 in vehicle controls), corresponding to a 58.5% reduction.
Reduced average tumor weight to 0.65 g (vs. 1.26 g in vehicle controls), corresponding to a 48.4% reduction.
Downregulated levels of phosphorylated mTOR, phosphorylated Akt, and HK2 in tumor tissue.
Caused slightly lower average body weight than controls with no evident signs of toxicity.
-
Animal Model:athymic nude mice (5-week-old female)[3]
-
Dosage:40 mg/kg
-
Administration:i.p.; daily; 15 days
-
Result:Reduced average tumor volume to 420.53 mm3, compared to 894.79 mm3 in vehicle controls.
Reduced average tumor weight to 0.26 g, compared to 0.73 g in vehicle controls.
Decreased tumor microvessel density (CD31 staining) by 75.68% relative to vehicle controls.
Decreased Ki-67 proliferation index by 57.82% relative to vehicle controls.
Did not affect mouse body weight or cause pathological changes in liver, lung, kidneys, or spleen.
-
Animal Model:C57BL/6 mice[3]
-
Dosage:2.5 μM; 5 μM
-
Administration:s.c.; single dose
-
Result:Decreased VEGF-induced microvessel number in Matrigel plugs by 69.20% at 2.5 μM relative to VEGF-only controls.
Decreased VEGF-induced microvessel number in Matrigel plugs by 84.62% at 5 μM relative to VEGF-only controls.
Chemical Information
-
CAS. Nr. 2779545-15-0
-
Molecular Weight 346.50
-
Formel C22H34O3
-
SMILES
C[C@@]12[C@H]([C@](O)(CC[C@@]1([H])C(C)(CCC2)C)C)CC3=C(C=C(C=C3O)O)C
-
Structure Classification
-
Initial Source
Dictyopteris divaricata Okam
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
Reinheit & Dokumentation
Verweise
[1]. Deng Q, et al. Neoalbaconol induces energy depletion and multiple cell death in cancer cells by targeting PDK1-PI3-K/Akt signaling pathway. Cell death & disease. 2013 Sep 19;4(9):e804. [Content Brief]
[2]. Yu X, et al. Neoalbaconol induces cell death through necroptosis by regulating RIPK-dependent autocrine TNFα and ROS production. Oncotarget. 2015 Feb 10;6(4):1995-2008. [Content Brief]
[3]. Yu X, et al. Neoalbaconol inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production. Molecular carcinogenesis. 2017 May;56(5):1414-1426. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)